Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early urinary kallidinogenase use with endovascular treatment for acute anterior circulation large vessel occlusion stroke
ChiCTR1900020671Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- Jan 2019
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Human urinary kallidinogenase in ischemic stroke and Large-Vessel Ischemic Stroke (LVO) (2 arms), sponsored by Army Medical University. Primary endpoints: Modified Rankin Scale score at 90 days and Symptomatic intracerebral hemorrhage rate. Started Jan 2019; status: recruiting.
02
Drugs
Human urinary kallidinogenase
03
Conditions
ischemic strokeLarge-Vessel Ischemic Stroke (LVO)
Beyond the preview
Go deeper on ChiCTR1900020671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020671.